 |
市場調查報告書
商品編碼
1190091
生物工藝容器市場 - COVID-19 的增長、趨勢、影響和預測 (2023-2028)Bioprocess Containers Market - Growth, Trends, and Forecasts (2023 - 2028) |
||||||
※ 本網頁內容可能與最新版本有所差異。詳細情況請與我們聯繫。
在預測期內，生物工藝容器市場預計將以 12.2% 的複合年增長率增長。
最初，COVID-19 大流行的出現對生物工藝容器市場產生了重大影響，因為世界各地的封鎖影響了設備、原材料和其他所需產品的供應鏈。針對 COVID- 19個正在引起關注。 此外，由於生物工藝容器在疫苗的研發和生產中發揮著非常重要的作用，私人公司和政府機構對疫苗進行了巨額投資，對市場產生了重大影響。 例如，2021 年 7 月發布的 PubMed 數據顯示，流行病防範創新聯盟 (CEPI) 已投資 56 億美元開發 COVID-19 疫苗，其中約有 511 億美元的預購協議 (APA)。花費。 因此，在如此巨大的投資下，疫情對所研究的市場產生了相當大的積極影響。
市場增長的主要驅動因素是全球癌症和免疫疾病病例的流行率不斷上升，需要疫苗和生物製劑，免疫療法和化學療法刺激了對生物工藝容器的需求，同時人們對生物工藝容器的偏好也在增加。 例如，根據美國癌症協會 2022 年 4 月的一份報告，生物製劑以多種方式用於治療癌症，並被廣泛用於治療。
此外，2022年8月，中國的信達生物和總部位於巴黎的賽諾菲向生物製藥集團投資24.2億美元，共同在中國開發兩種抗癌藥物。。 信達生物表示，SAR408701（tusamitamab ravtansine）用於治療肺癌、胃癌等多種癌症，SAR444245（non-alpha IL-2）用於皮膚癌、頭頸腫瘤等的II期臨床試驗。被告知它在裡面。 因此，癌症負擔的增加和治療藥物開發的資金預計將推動被調查市場的增長。
此外，該地區公司的其他業務擴張努力（例如擴張、合併、收購和合作）預計將在預測期內進一步推動生物工藝容器市場的增長。 例如，2022 年 6 月，阿斯利康罕見病部門亞力兄宣布，將在未來 18 個月內斥資約 6500 萬歐元（68□□20 萬美元）擴大其在愛爾蘭的製造能力，這筆投資將被該公司用於提高其在該國的生物製劑製造能力，並推動其研發計劃。 生物工藝容器可以很容易地集成到生物製劑製造中的各種高性能係統中。 因此，由於上述因素，預計在預測期內對生物過程容器的需求將增加，市場有望增長。
此外，疫苗是用於治療各種疾病的最重要的生物製劑形式之一，公司正在大力投資開發針對包括罕見病在內的多種疾病的疫苗。因此，有望進一步推動市場增長。 例如，2021 年 10 月，瑞典投資公司 Flerie Invest 投資 5200 萬美元，在瑞典北部的 Matfors 建立先進疫苗和生物製劑的創新中心。 疫苗生產需要更好的液體處理設備來滿足無污染需求。 生物工藝容器滿足這些參數，增加了它們對疫苗生產的需求。
因此，由於上述因素，預計生物過程容器市場在預測期內將會增長。 然而，與設備相關的高成本加上□□可浸出/可提取的相關雜質問題和嚴格的法規預計將在預測期內限制生物工藝容器市場的增長。
主要市場趨勢
在預測期內，二維生物工藝容器部分預計將佔據主要市場份額
由於 2D 生物工藝容器部分能夠加快現有的生物製藥生產過程，並且有助於介質製備、流體管理和產品儲存，因此預計將在調查的市場中佔據很大份額。
二維生物工藝容器廣泛用於散裝藥物和散裝藥物前體的細胞採集和輸送。 因此，對開發和擴大生物製品生產的投資預計將增加對二維生物工藝容器的需求，從而有望推動該領域的增長。 多家公司提供先進的 2D 生物工藝容器，包括 Thermo Fisher、Servios 和 Cole Palmer。
對更多生物製劑開發和生產的投資不斷增加，迫使生物工藝容器製造商加強其產品和擴大生產能力，這將對二維生物工藝容器領域產生積極影響。 例如，2022 年 2 月，ALLpaQ 包裝集團宣布推出全新系列的 ALLpaQ 500 PLUS 生物工藝容器。 公司宣布將對生物工藝容器進行投資，以引領市場並滿足客戶需求。
因此，隨著主要參與者投資生物工藝容器業務，預計該領域在未來幾年將呈現強勁增長。
預計在預測期內北美地區將佔據主要市場份額
北美地區是一些最大的製藥和生物製品公司的所在地，這些公司積極從事生物製品的開發和生產。
此外，由於政府的舉措，慢性病的高負擔和對生物製藥的高需求也有望推動市場增長。 例如，2021 年 5 月，魁北克省成為加拿大第四個實施強制性生物仿製藥轉換計劃的省份。 除了一些例外，該州已轉為僅允許其批准的生物製劑清單上的生物仿製藥（如果有）的政策。 因此，這些努力有望促進生物製劑的採用，並對生物工藝容器市場產生重大積極影響，推動市場增長。
在北美地區，由於美國對生物製劑的大量投資和大量的生物製劑批准以及慢性病負擔的增加，美國在生物工藝容器市場佔有非常大的市場份額。預計佔據 例如，2021 年 7 月，Cytiva 和 Pall Corporation 計劃在兩年內投資約 15 億美元擴大產能，以滿足對生物技術產品不斷增長的需求。 根據 Cytiva 的新聞稿，在包括中國、歐洲和美國在內的亞太地區，層析樹脂的價值超過 6 億美元，細胞培養基的價值超過 4 億美元，生物反應器等一次性技術的價值超過 3 億美元。計劃投資超過2億美元擴大其在
同樣，2022 年 4 月，Catalent 宣布計劃在其位於印第安納州布盧明頓的工廠投資約 3.5 億美元，以擴大其生物原料藥和產品製造能力。底部。 該項目通過增加新的生物反應器、注射器灌裝線和由質量控制實驗室和復雜的自動化包裝支持的冷凍乾燥能力，解決了行業強大的跨模式生物製劑管道。
因此，由於上述因素，預計北美地區將在生物工藝容器市場佔據主要份額，其中美國是預測期內生物工藝容器的主要市場。
競爭格局
全球生物工藝容器市場競爭適中。 目前在市場份額方面佔據市場主導地位的幾家知名企業正在收購產品，與其他企業合作以鞏固其在全球市場的地位，並推出新產品。 目前主導市場的公司包括 Thermo Fisher Scientific Inc、Danaher Corporation (Cytiva)、Saint-Gobain S.A、Lonza Group AG 和 Avantor Inc。
其他好處
- Excel 格式的市場預測 (ME) 表
- 三個月的分析師支持
內容
第1章介紹
- 研究假設和市場定義
- 調查範圍
第2章研究方法論
第 3 章執行摘要
第4章市場動態
- 市場概覽
- 市場驅動力
- 增加對生物製品的需求並降低交叉污染的風險
- 使用一次性技術生產疫苗
- 市場製約因素
- 設備成本高以及與可浸出物/可萃取物相關的雜質問題
- 針對使用生物工藝容器的製造設施制定嚴格的監管框架
- 波特的五力分析
- 新進入者的威脅
- 買方/消費者議價能力
- 供應商的議價能力
- 替代品的威脅
- 競爭公司之間的敵對關係
第 5 章市場細分
- 按容器類型
- 二維生物工藝容器
- 3D 生物工藝容器
- 其他容器和配件
- 通過使用
- 上游過程
- 下游過程
- 流程開發
- 最終用戶
- 生物製藥公司
- 生命科學研究與開發公司
- 其他最終用戶
- 按地區細分
- 北美
- 美國
- 加拿大
- 墨西哥
- 歐洲
- 德國
- 英國
- 法國
- 意大利
- 西班牙
- 其他歐洲地區
- 亞太地區
- 中國
- 日本
- 印度
- 澳大利亞
- 韓國
- 其他亞太地區
- 中東和非洲
- 海灣合作委員會
- 南非
- 其他中東地區
- 南美洲地區
- 巴西
- 阿根廷
- 其他南美洲
- 北美
第6章競爭格局
- 公司簡介
- Thermo Fisher Scientific Inc.
- Cytiva
- Saint-Gobain S.A
- Lonza Group AG
- Avantor Inc
- Merck KGaA
- Sartorius AG
- CellBios Healthcare and Lifesciences Pvt Ltd
- Cole-Parmer Instrument Co
- Biomass Sensor Singapore Pte
第7章 市場機會與今後動向
The bioprocess containers market is anticipated to grow at a CAGR of 12.2% over the forecast period.
Initially, the emergence of the COVID-19 pandemic had a significant impact on the bioprocess containers market because lockdowns all over the globe affected the supply chain of instruments, raw materials, and other necessary products but research & development activities came into focus for the development of a vaccine against COVID-19. There was also huge investments by the various private as well as government entities in the area for the vaccines which had a significant impact on the market because bioprocess containers played a very crucial role in the vaccine development and production. For instance, data from PubMed published in July 2021 stated that Coalition for Epidemic Preparedness Innovations (CEPI) invested USD 5.6 billion in developing COVID-19 vaccines and about USD 51.1 billion was spent on advanced purchase agreements (APAs). Hence, with such huge investments, the pandemic had a considerable positive impact on the market studied.
The major factors attributing to the market's growth include the rising global prevalence of cancer and immunological disorder cases that necessitate the requirement for vaccines and biologics, coupled with the increased preference for immunotherapy and chemotherapy that fuels the demand for bioprocess containers. For instance, according to the April 2022 report of the American Cancer Society, biologics are used in the treatment of cancer in many ways and are being used widely for the treatment.
Additionally, in August 2022, Innovent Biologics of China and Paris-based Sanofi invested USD 2.42 billion in the biopharma group to jointly develop two cancer drugs in China. As per Innovent Biologics, SAR408701, or tusamitamab ravtansine, would be used to treat lung, gastric and other cancers, while SAR444245, or non-alpha IL-2, was under phase-II studies for skin cancer, head, and neck tumors, among others. Hence, the growing burden of cancer and funding in therapeutics development are expected to boost growth in the studied market.
In addition, the other business expansion initiatives by the companies in the area, such as expansion, mergers, acquisitions, and collaborations, are further expected to fuel growth in the bioprocess containers market over the forecast period. For instance, in June 2022, the Rare Disease division of AstraZeneca, Alexion, announced to spend about EUR 65 million (USD 68.20 million) to expand its manufacturing capabilities in Ireland over the next 18 months, the investment will be used by the company to build up its biologics manufacturing capacity and increase R&D initiatives in the country. Bioprocess containers are readily integrated in various high-performance systems during the production of biologics. Hence, owing to the above-mentioned factors, the demand for bioprocess containers is expected to increase over the forecast period and the market is expected to grow.
Furthermore, vaccines are one of the most important forms of biologics that are used in the treatment of various medical conditions, and companies are investing heavily in the development of vaccines for many diseases including rare ones which are further expected to boost the market growth. For instance, in October 2021, the Swedish investment company, Flerie Invest, invested USD 52 million to establish an innovation hub for advanced vaccines and biological drugs in Matfors in northern Sweden. During vaccine production, better liquid handling equipment is required that can manage the neccessity of no-contamination. These parameters are fulfilled by the bioprocess containers which is boosting the demand for the same during vaccine production.
Therefore, due to the above-mentioned factors, the bioprocess containers market is expected to grow over the forecast period. However, the high cost associated with the equipment coupled with impurity issues related to leachable and extractable and strict regulatory regulations are expected to restrain the growth of the bioprocess containers market during the forecast period.
Key Market Trends
2D Bioprocess Containers Segment is Expected to Hold the Major Market Share in the Market Over the Forecast Period
The 2D bioprocess containers segment is anticipated to hold a significant share of the market studied due to their capacity to expedite the existing biopharmaceutical production process and the fact that they are helpful for media preparation, fluid management, and storage of the produce.
For cell harvesting and delivering bulk drug products and bulk drug precursors, 2D bioprocess containers are used widely. Hence, with the investment in the development and expansion of biologics production, the demand for 2D bioprocess containers is expected to increase, which is anticipated to boost the segment's growth. Several companies offer advanced 2D bioprocess containers, such as Thermo Fisher, CellBios, and Cole-Palmer.
The rising investment in developing and producing more biologics is compelling the bioprocess container manufacturers to enhance their offerings and expand their capacity, which is expected to impact the 2D bioprocess containers segment positively. For instance, in February 2022, ALLpaQ Packaging Group announced the launch of its new range of ALLpaQ 500 PLUS Bioprocess Container. The company announced that the investment in bioprocess containers is made to lead the market and fulfill the client's requirements.
Hence, the segment is expected to witness strong growth in the coming years due to the key companies investing in the bioprocessing containers business.
North America Region is Expected to Occupy a Major Market Share in the Market Over the Forecast Period
The North American region is home to some of the largest pharmaceuticals and biopharmaceutical companies that are actively engaged in biologics development and production.
The high demand for biopharmaceutical products owing to the high burden of chronic diseases and government initiatives is also expected to boost the market growth. For instance, in May 2021, Quebec became the fourth Canadian province to implement a mandatory biosimilar switching program. With some exceptions, the province is switching to a policy of allowing only biosimilars on lists of approved biologics, if available. Hence, such initiatives promote the adoption of biologics which is expected to have a significant positive impact on the bioprocess containers market and fuel growth in the market.
In the North American region, United States is expected to hold a very significant market share in the bioprocess containers market owing to the massive investment in biologics and the high number of biologics approval in the country coupled with the rising burden of chronic diseases. For instance, in July 2021, Cytiva and Pall Corporation planned to invest about USD 1.5 billion over two years to expand their capacity to meet the growing demand for biotechnology products. As per the press release by Cytiva, over USD 600 million would be invested in chromatography resins, over USD 400 million in cell culture media, over USD 300 million in single-use technology, for example, bioreactors, and over USD 200 million for the expansion of their sites across China and the rest of the Asia-Pacific region, Europe, and United States.
Similarly, in April 2022, Catalent revealed its plan to invest about USD 350 million at its facility in Bloomington, Indiana, to expand biologics drug substance and product manufacturing capabilities. The project will serve the industry's robust biologics pipeline across various modalities with new bioreactors, syringe filling lines, and additional lyophilization capacity, supported by quality control laboratories and complex automated packaging.
Therefore, due to the above-mentioned factors, the North American region is expected to hold a significant share of the bioprocess containers market, with United States being a major market for bioprocess containers over the forecast period.
Competitive Landscape
The global bioprocess containers market is moderately concentrated in terms of competition. Some prominent players currently dominating the market in terms of market share are acquiring the products, entering into partnerships with other companies to consolidate their global market positions, and launching new products. Some companies currently dominating the market are Thermo Fisher Scientific Inc, Danaher Corporation (Cytiva), Saint-Gobain S.A, Lonza Group AG, and Avantor Inc.
Additional Benefits:
- The market estimate (ME) sheet in Excel format
- 3 months of analyst support
TABLE OF CONTENTS
1 INTRODUCTION
- 1.1 Study Assumptions and Market Definition
- 1.2 Scope of the Study
2 RESEARCH METHODOLOGY
3 EXECUTIVE SUMMARY
4 MARKET DYNAMICS
- 4.1 Market Overview
- 4.2 Market Drivers
- 4.2.1 Increasing Demand for Biologics and Lower Risk of Cross-Contamination
- 4.2.2 Vaccine Production Using Single-Use Disposable Technologies
- 4.3 Market Restraints
- 4.3.1 High Cost of Equipments Coupled with Impurity Issues Related to Leachables and Extractables
- 4.3.2 Stringent Regulatory Framework for Manufacturing Facilities with Bioprocess Containers
- 4.4 Porter's Five Forces Analysis
- 4.4.1 Threat of New Entrants
- 4.4.2 Bargaining Power of Buyers/Consumers
- 4.4.3 Bargaining Power of Suppliers
- 4.4.4 Threat of Substitute Products
- 4.4.5 Intensity of Competitive Rivalry
5 MARKET SEGMENTATION
- 5.1 By Type of Containers
- 5.1.1 2D Bioprocess Containers
- 5.1.2 3D Bioprocess Containers
- 5.1.3 Other Containers and Accessories
- 5.2 By Application
- 5.2.1 Upstream Process
- 5.2.2 Downstream Process
- 5.2.3 Process Development
- 5.3 By End-User
- 5.3.1 Biopharmaceutical Companies
- 5.3.2 Life Science R&D Companies
- 5.3.3 Other End-Users
- 5.4 By Geography
- 5.4.1 North America
- 5.4.1.1 United States
- 5.4.1.2 Canada
- 5.4.1.3 Mexico
- 5.4.2 Europe
- 5.4.2.1 Germany
- 5.4.2.2 United Kingdom
- 5.4.2.3 France
- 5.4.2.4 Italy
- 5.4.2.5 Spain
- 5.4.2.6 Rest of Europe
- 5.4.3 Asia-Pacific
- 5.4.3.1 China
- 5.4.3.2 Japan
- 5.4.3.3 India
- 5.4.3.4 Australia
- 5.4.3.5 South Korea
- 5.4.3.6 Rest of Asia-Pacific
- 5.4.4 Middle East and Africa
- 5.4.4.1 GCC
- 5.4.4.2 South Africa
- 5.4.4.3 Rest of Middle East and Africa
- 5.4.5 South America
- 5.4.5.1 Brazil
- 5.4.5.2 Argentina
- 5.4.5.3 Rest of South America
- 5.4.1 North America
6 COMPETITIVE LANDSCAPE
- 6.1 Company Profiles
- 6.1.1 Thermo Fisher Scientific Inc.
- 6.1.2 Cytiva
- 6.1.3 Saint-Gobain S.A
- 6.1.4 Lonza Group AG
- 6.1.5 Avantor Inc
- 6.1.6 Merck KGaA
- 6.1.7 Sartorius AG
- 6.1.8 CellBios Healthcare and Lifesciences Pvt Ltd
- 6.1.9 Cole-Parmer Instrument Co
- 6.1.10 Biomass Sensor Singapore Pte
